oki-219
·Code: OKI-219
oki-219: 1 clinical trial tracked.
oki-219 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about oki-219, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer
Primary endpoint: Identify maximum tolerated dose (MTD) of OKI-219 in monotherapy
InterventionalRandomizedopen200 targetStarted 2024-02Completion 2027-0833 sites · Belgium, France, Italy, South Korea…OnKure, Inc.